To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Introduction: The National Institute of Clinical Excellence (NICE) currently recommends using the 21-gene Oncotype DX assay to help guide decisions about chemotherapy (CT) after surgery in some patients with lymph node negative early breast cancer.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Magnus
Contact Magnus, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack